Ovarian cancer is among the deadliest gynecologic cancers, associated with a low 3-year rate of survival due to its typically late diagnosis.

Current assessments in clinical practice primarily rely on histological and pathological evaluation, which neither accurately predict outcomes nor provide personalized treatment strategies.

We are conducting research on the discovery of novel biomarkers for early prognosis and elucidation of novel therapeutic targets.

Our recent presentation:

Wu, H.T. and Tsurumi A. “Ovarian Cancer Survival Outcomes with Novel Prediction Biomarkers.” Mass General Brigham Clinical Research Day, Oct. 2024.